Patient Assistance Introduction
This page includes resources for health care professionals to share with patients using REMICADE® (infliximab) and their family members and caregivers. Please click on any of the links below to get more detailed information.
Open Enrollment Brochure. Even if patients keep the same health plan, benefits can change. The information in the Open Enrollment brochure can help patients make sure they have the coverage needed beginning January 1, 2015.
Janssen Prescription Assistance for REMICADE® (infliximab). This page has information about prescription assistance programs sponsored by relevant Janssen Pharmaceutical Companies as well as up-to-date information about independent foundations that may have available funding to help minimize drug costs for REMICADE®.
Johnson & Johnson Patient Assistance Foundation. Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is committed to providing access to medicines for uninsured individuals who lack the financial resources to pay for them. If your patient needs REMICADE® (infliximab), and is uninsured and unable to pay for their medicine, please have them contact a JJPAF program specialist at 1-800-652-6227 9 AM to 6 PM ET or visit the foundation website at JJPAF.org to see if they might qualify for assistance.
RemiStart®. RemiStart® is a patient rebate program that supports your access to REMICADE® (infliximab). Based on your eligibility, RemiStart® can provide a rebate for your medication out-of-pocket costs, including deductible, co-payment, and co-insurance. If eligible, you will be responsible for $50 per infusion and will receive a rebate for the remaining medication out-of-pocket costs, for up to 12 months from the first eligible date of service or a maximum annual benefit of $8000, whichever comes first. Eligible patients must be beginning or currently receiving treatment with REMICADE® and must have commercial insurance that covers medication costs for REMICADE®. Patients enrolled in Medicare, Medicaid, or other federally funded programs are not eligible to participate. To enroll, patients should submit a completed enrollment form (editable) to RemiStart®. Click to view the full patient brochure and Medication Guide. For additional information, including eligibility and restrictions, please visit RemiStart.com or click to view the RemiStart Flashcard.
RemiStart® Extended Access Program. RemiStart® Extended Access is a patient rebate program for those who have participated in the RemiStart® Program and have exhausted the 12 months in the program. In order to be eligible for Extended Access, you must have met the eligibility requirements of the RemiStart® Program. If eligible, you will be responsible for $50 per infusion and will receive a rebate for the remaining medication out-of-pocket costs, for up to 12 months from your re-enrollment or a maximum annual benefit of $8000, whichever comes first. To enroll, please submit a completed enrollment form (editable) to the RemiStart® Extended Access Program. Click to view the full patient brochure and Medication Guide. For additional information, including eligibility and restrictions, please visit RemiStart.com.
Patient Support Links. This section of the site has a list of other web resources to help your patients and their families understand and manage therapy with REMICADE® and their disease.